Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for RM-718 in Acquired hypothalamic obesity (HO). The expected timing is based on the latest available company guidance and may change.
3/25/24- First patient dosed. Preclinical data at ENDO'24. 8/5/25- First participant enrolled in Part C. Complete enrollment in Q1 2026. 11/04/25:- RM-718 Ph1C HO reiterated enrollment completes Q1 2026. 02/26/26:- Enrollment for RM-718 Phase 1/2 Part C in acquired HO reiterated to complete in Q1 2026. 05/05/26:- RM-718 Phase 1/2 Part C results in acquired HO expected mid-2026. 08/04/26:- RM-718 Part C data showed 11.6% BMI reduction at Week 16.
Verification
Confirm timing and program details against the company announcement or filing.